MaxCyte Inc
LSE:MXCT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
MaxCyte Inc
LSE:MXCT
|
US |
|
A
|
Anglo American Platinum Ltd
SWB:RPH1
|
ZA |
|
D
|
Daikin Industries Ltd
XBER:DKI
|
JP |
|
USANA Health Sciences Inc
NYSE:USNA
|
US |
|
B
|
Bank of China Ltd
DUS:W8V
|
CN |
|
Iron Mountain Inc
NYSE:IRM
|
US |
|
Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
|
US |
|
Datatec Ltd
F:DTT0
|
ZA |
|
Geberit AG
F:GBRA
|
CH |
MaxCyte Inc
MaxCyte sells cell-engineering tools that let scientists and drug makers move DNA, RNA, proteins, and other material into living cells. Its main product is an electroporation platform, along with disposable cartridges and related support services. The company’s customers are biotech and pharmaceutical firms, especially teams developing cell therapies and gene-edited medicines, as well as research labs that need reliable ways to modify cells. The business makes money in two main ways: by selling instruments and consumables, and by licensing its platform to drug developers. The consumable cartridges create repeat business as customers keep using the system in their labs and manufacturing workflows. The licensing model is important because it ties MaxCyte to the success of partner programs without making the company itself a drug developer. What makes MaxCyte different is that it sits at a key step in the cell-therapy value chain. It does not sell finished medicines; it sells the tools and know-how used to engineer the cells that become those medicines. That gives it a mix of equipment-style sales and recurring revenue from consumables and partner relationships, which is unusual for a life-science tools company.
MaxCyte sells cell-engineering tools that let scientists and drug makers move DNA, RNA, proteins, and other material into living cells. Its main product is an electroporation platform, along with disposable cartridges and related support services. The company’s customers are biotech and pharmaceutical firms, especially teams developing cell therapies and gene-edited medicines, as well as research labs that need reliable ways to modify cells.
The business makes money in two main ways: by selling instruments and consumables, and by licensing its platform to drug developers. The consumable cartridges create repeat business as customers keep using the system in their labs and manufacturing workflows. The licensing model is important because it ties MaxCyte to the success of partner programs without making the company itself a drug developer.
What makes MaxCyte different is that it sits at a key step in the cell-therapy value chain. It does not sell finished medicines; it sells the tools and know-how used to engineer the cells that become those medicines. That gives it a mix of equipment-style sales and recurring revenue from consumables and partner relationships, which is unusual for a life-science tools company.
Revenue: MaxCyte reported first-quarter revenue of $9.7 million, which met management’s expectations but was down 7% from $10.4 million a year ago because of weaker core revenue.
Core pressure: Core revenue fell 25% to $6.2 million as inventory management at the largest SPL customer and discontinued SPL programs weighed on the quarter.
Guidance: The company reiterated full-year 2026 guidance for $30 million to $32 million of total revenue, including $25 million to $27 million of core revenue and $5 million of SPL milestones and royalties.
New products: Management said ExPERT DTx is off to a good start and SeQure is gaining traction, with both products expected to contribute more in the second half and beyond.
Margins and costs: Operating expenses dropped sharply to $14.3 million from $21.2 million a year ago, and management said the 2025 restructuring is now fully flowing through the P&L.
Capital return: The board authorized a $10 million share repurchase program, and management said it expects to execute most of it by year-end.
